LOW-PERMEABILITY, LASER-ACTIVATED DRUG DELIVERY DEVICE
    1.
    发明申请
    LOW-PERMEABILITY, LASER-ACTIVATED DRUG DELIVERY DEVICE 有权
    低渗透性,激光激活药物递送装置

    公开(公告)号:US20120035528A1

    公开(公告)日:2012-02-09

    申请号:US13023370

    申请日:2011-02-08

    IPC分类号: A61M37/00 B65B1/04

    摘要: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.

    摘要翻译: 一种可植入药物递送装置,其使用多个储存元件来容纳和释放剂量的活性药物成分。 该装置包括第一壳单元,其具有第一封闭空腔体积并形成低渗透屏障。 第一壳元件被配置为吸收来自激光源的光照射,激光照射引起第一壳元件中的破裂。 第一活性药物成分包含在第一封闭空腔体积中,并且当第一壳元件被破坏时被释放。 该装置还包括第二壳单元,其具有第二封闭空腔体积并且还形成低渗透屏障。 第二活性药物成分包含在第二封闭空腔体积中。 该装置还包括包含第一和第二壳单元的包络元件。

    Low-permeability, laser-activated drug delivery device
    2.
    发明授权
    Low-permeability, laser-activated drug delivery device 有权
    低渗透性,激光激活药物输送装置

    公开(公告)号:US08911426B2

    公开(公告)日:2014-12-16

    申请号:US13023370

    申请日:2011-02-08

    摘要: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.

    摘要翻译: 一种可植入药物递送装置,其使用多个储存元件来容纳和释放剂量的活性药物成分。 该装置包括第一壳单元,其具有第一封闭空腔体积并形成低渗透屏障。 第一壳元件被配置为吸收来自激光源的光照射,激光照射引起第一壳元件中的破裂。 第一活性药物成分包含在第一封闭空腔体积中,并且当第一壳元件被破坏时被释放。 该装置还包括第二壳单元,其具有第二封闭空腔体积并且还形成低渗透屏障。 第二活性药物成分包含在第二封闭空腔体积中。 该装置还包括包含第一和第二壳单元的包络元件。

    Compositions and methods for selective inhibition of VEGF
    5.
    发明授权
    Compositions and methods for selective inhibition of VEGF 有权
    选择性抑制VEGF的组合物和方法

    公开(公告)号:US08470792B2

    公开(公告)日:2013-06-25

    申请号:US12631078

    申请日:2009-12-04

    摘要: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

    摘要翻译: 本文公开了可用于抑制血管内皮生长因子(VEGF)同种型表达的siRNA组合物和方法。 这样的组合物和方法还涉及能够选择性地靶向血管生成VEGF同种型的siRNA,同时选择性地节省抗血管生成同种型。 通过施用如所公开的小干扰RNA可以治疗涉及由VEGF过度表达刺激的血管生成的疾病,例如糖尿病性视网膜病变,年龄相关性黄斑变性和许多类型的癌症。

    METHOD FOR TREATING INTRAOCULAR NEOVASCULAR DISEASES
    7.
    发明申请
    METHOD FOR TREATING INTRAOCULAR NEOVASCULAR DISEASES 审中-公开
    治疗室间性新生血管疾病的方法

    公开(公告)号:US20070190058A1

    公开(公告)日:2007-08-16

    申请号:US11738284

    申请日:2007-04-20

    申请人: Naveed Shams

    发明人: Naveed Shams

    IPC分类号: A61K39/395

    摘要: A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of VEGF antagonist, followed by less frequent dosing of a therapeutically effective amount of VEGF antagonist.

    摘要翻译: 提供了一种方法,其给予患有或有风险的眼内新生血管障碍的哺乳动物,其中定期给予治疗有效量的VEGF拮抗剂,随后治疗有效量的VEGF拮抗剂的频率较低。